Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease.

ABSTRACT:

Background

Data on effects of intra-gastric balloon (IGB) on metabolic dysfunction-associated steatotic liver disease (MASLD) are scarce, in part with contradictory results, and mainly obtained in tertiary care patients with diabetes and other comorbidities. We here explore effects of IGB in patients with MASLD referred to a first-line obesity clinic.

Methods

In this prospective cohort study, patients with at least significant fibrosis (≥ F2) and/or severe steatosis (S3) according to screening transient elastography (FibroScan®) were offered a second FibroScan® after 6 months lifestyle modification with or without IGB (based on patient preference).

Results

50 of 100 consecutively screened patients (generally non-diabetic) qualified for repeated evaluation and 29 (58%)

SUBMITTER: van Dijk AM 

PROVIDER: S-EPMC10635963 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature